Kiniksa Pharmaceuticals Ltd Class A (NASDAQ:KNSA)

North American company
add to virtual portfolio
trade
This share can be held in
Trading AccountISAJISASIPP

Share Price Chart

- Chart currently unavailable -

Market Info - KNSA

  • Market Open Price0.00
  • Previous Close0.00
  • Volume-
  • 52w Low/High-
  • Last Trade Price0.00
  • Bid/Ask Price0.00

Company Info - KNSA

  • Market Cap$1.178bn
  • SymbolNASDAQ:KNSA
  • IndustryHealthcare
  • SectorBiotechnology
  • Currency
  • ISINBMG5269C1010

Company Profile

Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases.Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, a debilitating inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, KPL-045, KPL-404 are other monoclonal antibodies.Kiniksa Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases.

Latest KNSA news

Currently there for this company. Visit our news hub for other news .